Clinical Experience with α-Particle–Emitting (211)At: Treatment of Recurrent Brain Tumor Patients with (211)At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

α-Particle–emitting radionuclides, such as (211)At, with a 7.2-h half-life, may be optimally suited for the molecularly targeted radiotherapy of strategically sensitive tumor sites, such as those in the central nervous system. Because of the much shorter range and more potent cytotoxicity of α-parti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Zalutsky, Michael R., Reardon, David A., Akabani, Gamal, Coleman, R. Edward, Friedman, Allan H., Friedman, Henry S., McLendon, Roger E., Wong, Terence Z., Bigner, Darell D.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2832604/
https://ncbi.nlm.nih.gov/pubmed/18077533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.046938
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados